Physician profile
Arvind Viradia
NPI 1417947904
$6,004.08
in general payments reported to CMS, 2019-2025
32 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,683 · 2020: $502 · 2021: $817 · 2022: $751 · 2023: $802 · 2024: $1,015 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,251.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,251.05 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $572.81 | 2021-2024 | Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $503.99 | 2019-2022 | |
| Amarin Pharma, INC. | $501.89 | 2019-2022 | |
| Lilly USA, LLC | $388.09 | 2019-2024 | Jardiance, Mounjaro, Trulicity |
| Novo Nordisk INC | $321.56 | 2019-2025 | Ozempic |
| Sanofi-Aventis U.S. LLC | $312.39 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $251.06 | 2019-2022 | |
| Glaxosmithkline, LLC. | $240.05 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Biohaven Pharmaceuticals, INC. | $211.93 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $199.98 | 2021-2024 | |
| Teva Pharmaceuticals USA, INC. | $193.28 | 2019-2023 | Austedo Xr |
| Amgen INC. | $169.51 | 2019-2025 | Repatha, Otezla, Uplizna |
| Lexicon Pharmaceuticals, INC. | $143.46 | 2023-2024 | Inpefa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.94 | 2019-2024 | Xifaxan |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $75.45 | 2024 | Voquezna |
| Biohaven Pharmaceutical Holding Company Ltd. | $68.94 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.90 | 2019-2023 | Jardiance |
| Allergan, INC. | $61.53 | 2020 | |
| Pfizer INC. | $55.25 | 2023 | |
| Corcept Therapeutics | $54.67 | 2025 | Korlym |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.42 | 2024-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $50.33 | 2019-2021 | |
| Mylan Specialty L.P. | $31.07 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $29.43 | 2023-2024 | Gemtesa |
| Scpharmaceuticals INC. | $22.25 | 2024 | |
| Shield Therapeutics INC | $18.17 | 2024 | |
| Nestle Healthcare Nutrition INC. | $14.57 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.57 | 2023 | Quviviq |
| Eisai INC. | $12.70 | 2021 | |
| Ironwood Pharmaceuticals, INC | $12.08 | 2020 | |
| Sunovion Pharmaceuticals INC. | $11.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Viradia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.